SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

$SWTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $SWTX alert in real time by email

STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion.

"Martin is a proven industry leader whose experience in developing and delivering novel treatments to patients in need is exceptional," said Saqib Islam, Chief Executive Officer of SpringWorks. "His expertise in rare diseases and unique perspectives leading multiple Research and Development organizations across the globe will be extremely valuable to SpringWorks as we advance and expand our pipeline and execute on our mission to make a meaningful difference in patients' lives. I am delighted to welcome Martin to the SpringWorks team."

"I am very pleased to join the SpringWorks Board and work with a group of talented and visionary leaders who are driven by a joint mission to develop and deliver transformative therapies for patients with devastating diseases," said Dr. Mackay. "I believe SpringWorks is uniquely positioned to make a significant impact in therapeutic areas with tremendous potential, and it is an honor to bring my experience and knowledge to support the important work that SpringWorks is doing."

Dr. Mackay is a co-founder and Executive Chairman of Rallybio, a privately held clinical-stage biotechnology company focused on severe rare diseases that was incorporated in January 2018. Previously, Dr. Mackay was Executive Vice President, Head of Research and Development at Alexion from 2013 until 2017. Prior to joining Alexion, Dr. Mackay served as President, Research and Development at AstraZeneca from 2010 to 2013, where he led the R&D functions worldwide, including discovery research, clinical development, regulatory affairs, and key related R&D functions. From 1995 to 2009, he held various positions at Pfizer Inc., including Senior Vice President of Worldwide Development, where he was a member of the Executive Leadership Team and led a global organization tasked with advancing a portfolio of investigational medicines across a range of disease areas, and President, Head of Pfizer Pharmatherapeutics, R&D, where he oversaw all aspects of small molecule discovery and development across multiple therapeutic areas. From 1986 to 1995, Dr. Mackay worked at Ciba-Geigy (now Novartis) in the United Kingdom and Switzerland, and held various positions in academic research prior to that time. Dr. Mackay is currently a member of the Board of Directors of Charles River Laboratories and Novo Nordisk. He received a First-Class Honours Degree in microbiology from Heriot-Watt University and his Ph.D. in molecular genetics from the University of Edinburgh.

About SpringWorks Therapeutics

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company's first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.

For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.

Contacts:

Kim Diamond

Vice President, Communications and Investor Relations

Phone: 203-561-1646

Email: kdiamond@springworkstx.com

Samantha Hilson Sandler

Senior Director, Investor Relations

Phone: 203-461-5501

Email: samantha.sandler@springworkstx.com



Primary Logo

Get the next $SWTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SWTX

DatePrice TargetRatingAnalyst
11/20/2024$60.00Outperform
Evercore ISI
2/5/2024$75.00Buy
Guggenheim
12/1/2022$45.00Buy
BofA Securities
9/8/2021$97.00 → $105.00Overweight
JP Morgan
8/5/2021$136.00 → $137.00Buy
HC Wainwright & Co.
More analyst ratings

$SWTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

    – Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi

    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over

    - Educational campaign aims to raise awareness and drive conversation about desmoid tumors, the devastating impact they have on patients' lives - STAMFORD, Conn., Feb. 19, 2025 /PRNewswire/ -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and Jennifer Fisher, jewelry designer and desmoid tumor patient advocate, are collaborating to increase understanding of desmoid tumors as well as to encourage patients to find a specialist, like an oncologist with experience treating desmoid tumors who can discuss available treatment options to manage their desmoid tumor. Desmoid tumors ar

    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

    – GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at:  https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86bhttps://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4944-8736-24cb19a5dec9https

    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SWTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SWTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SWTX
SEC Filings

See more

$SWTX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • November 27, 2023 - FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

    For Immediate Release: November 27, 2023 Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive. The tumor

    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • FDA Approval for OGSIVEO issued to SPRINGWORKS THERAPEUTICS INC

    Submission status for SPRINGWORKS THERAPEUTICS INC's drug OGSIVEO (ORIG-1) with active ingredient NIROGACESTAT has changed to 'Approval' on 11/27/2023. Application Category: NDA, Application Number: 217677, Application Classification: Type 1 - New Molecular Entity

    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SWTX
Leadership Updates

Live Leadership Updates

See more
  • SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

    STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. "Martin is a proven industry leader whose experience in developing and delivering novel treatments to patients in need is exceptional," said Saqib Islam, Chief Executive Officer of SpringWorks. "His expertise

    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer

    STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer. Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. "Tai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery

    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

    STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company's Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. ("AbbVie") until his retirement last year, brings over 30 years of experience in global commercial strategy and operations. "Carlos' success in building and leading global commercial organizations will be valuable as SpringWorks continues its planned transition into a commercial-stage compa

    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SWTX
Financials

Live finance-specific insights

See more
  • SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

    – Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi

    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

    STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcas

    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

    – Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validation of EU Marketing Authorization Application for mirdametinib for the treatment of adults and children with NF1-PN – – $498 million in cash, cash equivalents and marketable securities as of September 30, 2024; expected to fund the Company through profitability, which is anticipated in the first

    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SWTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more